A new review article in Frontiers argues that targeted therapies for atopic dermatitis (AD) should advance from symptom control toward endotype-driven precision medicine and durable disease modification.

The paper, "Targeted therapies in atopic dermatitis: toward endotype-driven precision medicine and disease modification," was published in Frontiers and frames AD treatment selection by molecular subtype rather than clinical severity alone. Endotype refers to a disease subtype defined by a distinct biological mechanism, in contrast to phenotype, which describes observable clinical features.

What does the review actually propose?

The title positions endotyping (the classification of disease by underlying immune pathway activity, such as Th2-dominant versus broader Th1/Th17/Th22 signatures) as the organizing principle for therapy selection. The authors contend that matching biologics or small-molecule inhibitors (oral drugs that block intracellular signaling enzymes such as Janus kinases) to a patient's endotype will outperform the current one-drug-first strategy. They extend the argument to disease modification, a term borrowed from rheumatology that implies altering the natural history of the condition rather than only suppressing signs and symptoms.

Dermatology has spent decades defining clinical phenotypes in AD through instruments such as SCORAD (Scoring Atopic Dermatitis, a composite severity index combining extent, intensity, and symptoms) and EASI. The endotype framework asks clinicians to overlay a molecular map on top of those scores. The two systems are not in competition, but the review implies that phenotype-only decision-making will eventually look like cardiology before the troponin assay, when chest-pain evaluation rested on clinical exam and electrocardiography alone.

What is missing from the framing?

The review, as its title indicates, is conceptual rather than a meta-analysis. It does not present pooled effect sizes (standardized measures of treatment impact, such as the standardized mean difference across trials) or head-to-head trial comparisons. The piece also does not name a single validated biomarker assay currently used in routine dermatology practice to assign an AD endotype. Without such an assay, the proposed endotype-driven model remains aspirational.

Readers should treat the article as a roadmap, not a synthesis of new data. The clinical-trial evidence underpinning today's targeted agents has been reviewed elsewhere, in publications with explicit inclusion criteria and effect-size reporting.

Why does the disease-modification claim carry weight?

The disease-modification question matters because regulators and payers increasingly distinguish between therapies that control symptoms during treatment and those that change the trajectory of a chronic condition after treatment stops. In atopic dermatitis, long-term off-treatment data (outcomes measured after a therapy is discontinued) remain sparse. Most pivotal trials measure EASI-75 (a 75% reduction in the Eczema Area and Severity Index, the standard AD severity score) or IGA 0/1 (clear or almost clear skin on the Investigator Global Assessment) at week 16 while patients continue active drug.

A genuine disease-modifying claim would require demonstrated persistence of clinical benefit, histologic normalization, or biomarker shift after withdrawal. The review's title signals that the field should now design trials with those endpoints, but the publication itself does not yet report such outcomes.

What should clinicians watch next?

The practical question is whether upcoming trials will adopt endotype stratification in their enrollment design. Such stratification would require a validated assay, regulatory acceptance of molecular subgroups, and payer coverage of the test itself. None of these prerequisites is established in the current review.

Until those building blocks are in place, the precision-medicine framing in the article will sit alongside, rather than replace, the current treat-to-target paradigm (a strategy in which treatment is escalated until a predefined severity goal is met). The review, taken on its own terms, is a call to redesign trial architecture rather than a verdict on the existing therapeutic arsenal. Whether the conceptual argument translates into measurable changes in prescribing will depend on biomarker validation studies and regulatory engagement, neither of which the current paper documents.